Assessment of the Clinical Utility of the NETest in a US Registry-Based Study Abstract #2202

Introduction: The clinical relevance of molecular biomarkers in oncology management has been recognized in breast and lung cancer. Current biomarkers in NET disease have limited clinical utility.
Aim(s): We evaluated the usefulness of a blood-based multigene biomarker assay in the management of neuroendocrine tumor disease (NETs) in a real-world study of a USA registry (RegisterNET: NCT02270567) of 100 patients. The NET liquid biopsy was investigated for diagnostic accuracy, and prediction of clinical disease status in 2 cohorts (treated and watch-and-wait).
Materials and methods: NET subjects (n=100) followed for 6 months. Gastroenteropancreatic (68%); lung 20%, and unknown origin (12%).Well-differentiated, low grade (97%), stage IV (96%); 70% had surgery; 56% drug treatment. NETest was measured at each visit and disease status was determined by RECIST. Scores categorized as low (NETest <40%) or high (>80%) defined disease as stable or progressive.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Professor Mark Kidd

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1497 Circulating Neuroendocrine Tumor Gene Signature, the NETest, Defines Therapy in GEP-NETs
Introduction: Early and precise delineation of therapeutic responses are key issues in GEP-NET management. Imaging has limitations in sensitivity while secretory biomarkers e.g., CgA is controversial.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Keywords: NETest, CgA, PCR
#1505 A Blood-Based Multi-Transcript Test, the NETest, Predicts and Defines PRRT Efficacy in Neuroendocrine Tumors
Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective NET treatment. Predicting response is based on somatostatin receptor expression and efficacy evaluated by RECIST criteria. Both have limited accuracy. The NETest measures tumor activity in blood and correlates cell signaling and metabolism directly with tumor activity.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Professor Mark Kidd
Authors: Bodei L, Kidd M, Severi S, Drozdov I, ...
Keywords: NETest, PRRT
#1521 Metastatic Disease in Gastroenteropancreatic Neuroendocrine Cancer: Incidence, Treatment and Survival
Introduction: Data on patients with metastatic disease from GEP-NETs are rare.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Ariana Madani
#1563 Impact of Early Surgery on Prognosis in Advanced Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET)
Introduction: In gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) the role of surgery remains to be determined.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD Patrizia Kump
#1878 Measurement in Blood of a Circulating NET mRNA Gene to Predict Surgical Efficacy
Introduction: Surgery is the only curative treatment for GEP-NETs, but identifying post-surgery residual disease is difficult and often delayed.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Professor Mark Kidd
Keywords: NETest, surgery, biomarker, NET